Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Exclusion Criteria

• •1. Laboratory-confirmed influenza infection during the past year documented by a positive PCR test in the Danish Microbiological database or anamnestic reported influenza infection in the same period
• •2. Active smoker
• •3. BMI \> 35 kg/m2
• •4. Women of childbearing potential not using safe contraception, or who are pregnant, or breast-feeding
• •5. Any allergies to components of or contraindication for Vaxigriptetra® or Flumist® incl. previous severe adverse reactions to influenza vaccinations or components of the vaccines
• •6. Use of immunosuppressive drugs\* within the past 6 months or who are currently using them
• •7. HIV, HBV, HCV laboratory confirmed active infection at screening visit
• •8. Have an acute illness, including an oral temperature ≥ 38°C, within 3 days prior to vaccination
• •9. Have received any vaccines, including live-attenuated vaccines within 4 weeks before inclusion, or plan receipt of such vaccines within 30 days following the inclusion
• •10. Any known malignant neoplasm within 5 years (except basal carcinoma of the skin).
• •11. Severe mental illness or linguistic issues which significantly impedes cooperation
• •12. Inability to provide written informed consent
• •* defined as: Azathioprin, methotrexate, cyclophosphamide, basiliximab, belimumab, anifrolumab, alemtuzumab, rituximab, mycophenolat, calcineurin inhibitors (ciclosporin, voclosporin and tacrolimus), mTOR inhibitors (everolimus and sirolimus), prednisolone (or any corticosteroid in doses above the equivalent of 5 mg prednisolone), TNF-α inhibitors (such as infliximab), anti-thymocyte globulin.